S

Scope Fluidics
SCP

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
PLN431.52M
EV
PLN323.24M
Shares Outstanding
3.17M
Beta
-0.01
Industry
Medical - Diagnostics & Research

Wall Street View

Analyst Rating
BUY
Analyst Target Price
Number of Analysts
1
P/E 2025E
-
P/Revenue 2025E
-

Historical 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Forecasted 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Margins & Returns

Gross Margin 2025E
-
Net Profit Margin 2025E
-5614.29%
ROE 2025E
-31.00%
ROCE 2024
57.57%

Dividends

DPS 2025E
PLN0.00
Payout Ratio 2025E
0.00%
Div. Yield 2025E
0.00%
DPS Last 3Y CAGR

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Scope Fluidics S.A.

gainify

S

Scope Fluidics S.A.

SCP

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010...

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Garstecki, Piotr

Employees

132

IPO Date

2017-08-01

Headquarters

Ogrodowa 58 Street, 9th floor, Warsaw 00-876, Poland

šŸ“Š Stock Price & Performance

The last closing price of Scope Fluidics (SCP) is PLN137.40, reflecting a -0.44% change from the prior session. Last updated: December 30, 2025 at 10:53 AM Eastern Time

Review the recent SCP stock performance trends:Past 1 Month: Scope Fluidics (SCP) shares have -7.60%.Past 3 Months: The stock has -19.41%.Past 6 Months: SCP shares have -8.96%. Last updated: January 1, 2026 at 12:20 AM Eastern Time

Over the last year, Scope Fluidics (SCP) has established a 52-week price range between a high of PLN197.00 and a low of PLN133.60. This metric is essential for assessing the stock's annual volatility. Last updated: January 1, 2026 at 12:20 AM Eastern Time

Scope Fluidics (SCP) is considered a low volatility stock. It has a beta of -0.01, which means it typically moves in the opposite direction of the broader market, with a magnitude of approximately 0.01 times the market's movement. Over the past 52 weeks, SCP has traded within a PLN133.60 – PLN197.00 range. Last updated: January 1, 2026 at 12:20 AM Eastern Time

Based on current SCP analyst forecasts and market assumptions, the consensus price target for Scope Fluidics (SCP) is PLN217.10 for 2027. Relative to the current price of PLN137.40, this implies a positive upside of +59.40%. Price targets reflect forward-looking estimates based on information available at the time and are inherently subject to change as underlying assumptions, company fundamentals, or market conditions evolve. Last updated: January 1, 2026 at 12:20 AM Eastern Time

A PLN1,000 investment in Scope Fluidics 5 years ago, when the stock was trading around PLN136.17, would be worth approximately PLN1009.03 today, based solely on share price performance (excluding dividends). This represents a total return of 0.90% over the period, equivalent to a compound annual growth rate (CAGR) of 0.18%. Past performance reflects historical price movements only and does not imply future results. Last updated: January 1, 2026 at 12:20 AM Eastern Time

šŸ’° Financial Metrics & Reports

The current Scope Fluidics (SCP) market capitalization is approximately PLN431.52M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Scope Fluidics's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:20 AM Eastern Time

In the most recently reported quarter, Scope Fluidics (SCP) generated PLN22.00K in revenue, representing a -8.33% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 4:30 AM Eastern Time

In the most recently reported fiscal year, Scope Fluidics (SCP) generated net income of PLN65.42M, compared with PLN-18.79M in the prior fiscal year, representing a -448.26% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of PLN-39.30M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 4:30 AM Eastern Time

According to its latest quarterly filing, Scope Fluidics (SCP) reported EBITDA of PLN-11.84M, representing a -47.69% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 4:30 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.02x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 4:30 AM Eastern Time

Based on the latest available data, Scope Fluidics (SCP) is currently trading at a last twelve months (LTM) P/E ratio of 6.88x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 4:30 AM Eastern Time

šŸ“… Earnings & Dividends

In the most recently reported quarter, Scope Fluidics (SCP) revenue was PLN22.00K, compared with analyst consensus expectations of PLN0.00. Earnings per share (EPS) for the quarter were PLN-4.17. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: šŸ‘‰ Estimates vs. Actuals Last updated: January 1, 2026 at 4:30 AM Eastern Time

Scope Fluidics (SCP) does not currently pay a dividend. Over the last twelve months (LTM), the company paid PLN0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 4:30 AM Eastern Time

šŸ“ˆ Analyst Information

Analyst assessments of whether Scope Fluidics (SCP) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: PLN137.40Consensus price target: PLN217.10Implied return: +59.40% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 4:30 AM Eastern Time

Based on the latest available analyst coverage, Scope Fluidics (SCP) currently carries a Buy consensus rating. Analysts' average SCP price target is PLN217.10. Relative to the current share price of PLN137.40, this suggests a potential price change of approximately +59.40%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 4:30 AM Eastern Time

Like other publicly traded stocks, Scope Fluidics (SCP) shares are bought and sold on stock exchanges such as WSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Scope Fluidics (SCP) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ā„¹ļø Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add SCP to your watchlist.

Scope Fluidics trades under the ticker symbol SCP on the WSE stock exchange. The ticker SCP is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Scope Fluidics (SCP) employs approximately 132 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: January 1, 2026 at 12:20 AM Eastern Time

Scope Fluidics (SCP) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Scope Fluidics (SCP) stock peers based on overlapping products, services, and competitive dynamics:Medicalgorithmics (MDG)Lifecare (LIFE)Molecure (MOC)Captor Therapeutics Spolka Akcyjna (CTX)Ryvu Therapeutics (RVU)Celon Pharma (CLN)Selvita (SLV)Synektik Spólka Akcyjna (SNT)Voxel (VOX)NEUCA (NEU) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Scope Fluidics.

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright Ā© 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Ā© 2026 Gainify. All rights reserved.